Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04892381
Other study ID # 13111993
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 18, 2021
Est. completion date April 22, 2022

Study information

Verified date May 2021
Source Cairo University
Contact Rana A Mosaad, Msc
Phone 201096344429
Email ranaahmedmosaad@gmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Assessment of Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients: A Case-Control Study


Description:

This prospective Case Control study will be conducted at Kasr Al-Aini Dermatology Outpatient Clinics and will include 30 LP patients and 30 normal healthy controls which will be recruited and assessed for eligibility for inclusion according to the above criteria. All participants (patients & controls) will be subjected to the following: - Written informed consent. - Detailed history including onset, course, duration of the disease and history of drug intake within 1 month before the eruption. - Clinical assessment of the Severity by using LP Severity Index (LPSI) (Kaur et al., 2020). - Skin biopsy will be taken under local anesthesia : - From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study. - From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study: i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area - The level of PD1 and PD-L1 will be detected using ELISA technique. - The lesional biopsy will be assessed by routine hematoxylin and eosin (H&E) to confirm the diagnosis of LP - Patients' serial numbers only will be used on data collection sheets and ELISA specimens' labels. Data will be entered on a computer with access limited to the researchers in order to ensure confidentiality of patients' information and lab results.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date April 22, 2022
Est. primary completion date April 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age group above 18 years old - Patients of both genders - Classic type of cutaneous LP. Exclusion criteria: - Topical treatment for LP 2 weeks before enrollment in the study or systemic treatment for LP 4 weeks before enrollment in the study and 3 years for systemic retenoids. - Actinic LP , LP pigmentosus and Mucosal only LP - Drug induced lichenoid eruption - Conditions precluding taking skin biopsy : bleeding tendency , lidocaine allergy - PD-1 associated-diseases e.g.: SLE, Cancers including melanoma and non-melanoma skin cancers, and Bullous Pemphigoid

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Skin Biopsy
Skin biopsy will be taken under local anesthesia : From each normal control; a 3 mm punch skin biopsy from a sun protected area will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study. From each LP patient; two punch skin biopsies will be taken and preserved in PBS and kept frozen at -80 degrees Celsius for ELISA study: i. The first biopsy will be a 3 mm punch biopsy from the center of LP lesional skin of sun protected area ii. The second biopsy will be a 3 mm punch biopsy from non lesional skin at least 15 cm away from the edge of any existing LP lesion of sun protected area The level of PD1 and PD-L1 will be detected using ELISA technique. The lesional biopsy will be assessed by routine hematoxylin and eosin (H&E) to confirm the diagnosis of LP

Locations

Country Name City State
Egypt Cairo University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measurement of the level of PD-1 and PD-L1 in the lesional and in non lesional skin in LP patients compared to normal controls Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Tissue Expression Levels in Lichen Planus Patients 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06021405 - Koebner's Phenomenon in Psoriasis and Lichen Planus N/A
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT05787925 - Adjunctive Oral Systemic Vitamin E Therapy on Salivary Nitric Oxide Level in Patients With Erosive Oral Lichen Planus N/A
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Completed NCT04952961 - Early Detection of Vulval CAncer Through Self-Examination (EDuCATE): Intervention Study N/A
Recruiting NCT04697563 - Laser Therapy in Women With Lichenoid Disorders N/A
Recruiting NCT06451744 - Cellular and Molecular Biomarkers in Patients With Lichen Planus N/A
Completed NCT03265093 - Use of Injectable Platelet Rich Fibrin in Lichen Planus N/A
Completed NCT03858634 - A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases Phase 2
Completed NCT02761122 - Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen) N/A
Active, not recruiting NCT00691106 - A Multi-center Study to Evaluate the Safety of Etanercept in the Treatment of Lichen Planus Phase 2
Terminated NCT05761158 - Study of the Characteristics of Pruritus in Patients With Frontal Fibrosing Alopecia or Lichen Planus Pilaris
Recruiting NCT02261662 - Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection N/A
Completed NCT05396261 - a Flexible Wound Dressing for the Management of Genital Skin Conditions N/A
Recruiting NCT02532166 - Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus N/A
Recruiting NCT06327620 - Treatment Of Oral Lichen Planus N/A
Completed NCT03796806 - Methods Validation Assessment for Study of Inflammatory Skin Disease
Completed NCT02850601 - Dexamethasone Solution for the Treatment of Oral Lichen Planus Phase 2
Not yet recruiting NCT01041625 - Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus Phase 2
Completed NCT00824889 - Exploratory Study of Natural Killer Cells in Human Skin N/A